COMMUNIQUÉS West-GlobeNewswire

Cytokinetics to Announce First Quarter Results on May 8, 2024
24/04/2024
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time. [...]
InnovAge Launches PACE Center in Los Angeles, Helping Seniors Live Independently with High-Quality Care
24/04/2024
Crenshaw Center Spotlights Impact of Participant-Centered, Coordinated Senior Care at No Cost to Eligible Seniors LOS ANGELES, April 24, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), the [...]
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
24/04/2024
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients DUBLIN, Ireland and BRIDGEWATER, N.J., [...]
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO ® (nirogacestat) in adults with desmoid tumors also accepted for [...]
LTC ACO Welcomes New Chief Operating Officer
24/04/2024
Country’s First Long-term Care Accountable Care Organization Appoints Michele Fronckiewicz to Executive Leadership Team KENNETT SQUARE, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- LTC ACO , the first Accountable Care [...]
Virbac : Public release of Virbac Annual Report at 31 December 2023 (ESEF format)
24/04/2024
Public release of Virbac Annual Report at 31 December 2023 (ESEF format). The Group released and filed its 2023 Annual Report with the French “Autorité des marchés financiers”. The document is also available on the [...]
Virbac : Communiqué de mise à disposition du Rapport Annuel au format ESEF au 31 décembre 2023
24/04/2024
Communiqué de mise à disposition du Rapport Annuel au format ESEF au 31 décembre 2023. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son Rapport Annuel au [...]
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
24/04/2024
Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
BrightInsight Recognized Among Newsweek’s World’s Best Digital Health Companies 2024 List
24/04/2024
SAN JOSE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- BrightInsight, Inc . , the trusted partner and de-facto platform driving value for top biopharma compliant digital health solutions, is thrilled to announce it has [...]
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
24/04/2024
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR [...]
NMDP to Present New Stem Cell Transplantation Data at the 2024 American Society of Clinical Oncology Annual Meeting
24/04/2024
MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR ® (Center for International Blood and Marrow Transplant Research ® ) will present new data on hematopoietic [...]
Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024
24/04/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) will publish its first quarter results in the morning of 3 May 2024. Later same day, the company will host a presentation for investors and analysts at 12:30 CET, where ALK’s [...]
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
24/04/2024
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- [...]
Global COVID-19 Memorial Will Honor Pandemic Frontline & Essential Workers
24/04/2024
CHICAGO, April 24, 2024 (GLOBE NEWSWIRE) -- A monument park and website honoring medical frontline and essential workers worldwide who risked their lives during the COVID-19 pandemic will break ground this summer in [...]
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the [...]
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
24/04/2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its [...]
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
24/04/2024
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo ® ( [...]
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
24/04/2024
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external [...]
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc [...]

Pages